WHEN DIAGNOSED WITH PROSTATE CANCER...
GENETIC PRECISION CAN GUIDE YOUR DECISIONS.

When Considering Tough Questions – Precision Matters

How aggressive is my cancer?

10-15% of men with prostate cancer have fast-growing, potentially lethal tumors.1
- Most men with prostate cancer die with the cancer and not from the cancer.
- Prolaris® is the leading molecular test that assesses prostate cancer aggressiveness and predicts outcomes.
- It delivers a personalized score to help your doctor provide individualized treatment recommendations.

Do hereditary factors affect my prostate cancer?

5-10% of all cancers develop because a person inherited a mutation in a cancer-causing gene that increases their risk.2
- Hereditary mutations such as those found in BRCA2 often cause a more aggressive form of prostate cancer.
- myRisk® is the leading hereditary cancer genetic test that assesses increased risk of aggressive prostate cancer and risk for secondary cancers.
- It provides a result that will help your doctor to determine your medical management.

When Making Treatment Decisions – Evidence Matters

What will Prolaris® tell me and my doctor?

Prolaris® test looks at 31 genes associated with prostate cancer and 15 genes for quality control.
- This provides critical, independent information beyond risk factors such as PSA, Gleason, and stage, which can lead to more precise treatment decisions.
- Prolaris® test results changed the treatment plans of 48%-65% of men with prostate cancer.3

What will myRisk® tell me and my doctor?

myRisk® test looks at 28 genes associated with hereditary cancer.
- It blends genetic testing and family history into a clinically actionable risk assessment.
- The test results help your doctor personalize your treatment.

At myriad - our tests provide precise next steps.

At myriad - our tests provide crucial insights.
When Considering the Long Term – Accuracy Matters

What’s the outlook for my survival?
ProLaris® is the best predictor of prostate cancer aggressiveness and addresses questions such as “will I die from this disease?”

What treatment is best for me?
ProLaris® provides independent information that can help you and your doctor make a more precise decision about your treatment options.
- Depending on your ProLaris® score, treatment options may include active surveillance, surgery, radiation, chemotherapy or a combination of treatments.

Am I at risk for a second cancer?
Men with prostate cancer associated with hereditary gene mutations also have an increased risk for a secondary cancer:

- Breast Cancer 6.8x greater than the general population
- Pancreatic Cancer 7x greater than the general population
- Melanoma and Colon Cancer Elevated Risk

- Knowing if you have a mutation helps your doctor provide a more specific risk assessment for you.

Is my family at risk for cancer?
myRisk also helps determine if family members may be at risk of developing hereditary cancer in the future.

Confidence is Key – When Decisions Matter

How confident can I be in ProLaris®?
ProLaris® is the #1 used genetic test for measuring prostate cancer aggressiveness.
ProLaris® has been extensively studied with 11 published in peer reviewed journals and validated studies in ~3000 patients:
- Validated in men with low, intermediate and high-risk prostate cancer as defined by the American Urological Association.

NCCN Guidelines suggest a molecular test like ProLaris® for men with localized prostate cancer.

How confident can I be in myRisk®?
myRisk® is the #1 hereditary cancer test in the world and the most extensively studied hereditary cancer diagnostic.
- myriad has tested more than 2.7 million patients for hereditary cancer risk assessment.

Quality and accuracy
myriad provides the highest quality, most accurate and actionable test results when making your most important decisions.

NCCN Guidelines for patients with prostate cancer at risk for hereditary mutation:
Prostate cancer patient with a Gleason Score of 7 or higher and family history.

If a doctor has 1000 prostate cancer survivors in their practice, 100 patients or more could be at increased risk for a second primary cancer due to a hereditary genetic abnormality.

myriad has been a trusted partner in molecular diagnostics for more than 25 years.
When Prostate Cancer Poses Pressing Questions...

At myriad, our tests provide the answers you and your doctor need.

If you are a patient or caregiver of someone recently diagnosed with prostate cancer visit prolaris.com to get started and talk to your doctor about Prolaris and myRisk tests from Myriad Genetics.

Take a 30-second quiz to learn about the risk of prostate cancer.

Visit myriad.com to find out more.

Copyright © Myriad Genetics, Inc. All rights reserved. myriad.com 8/2017